Recorded Webinar with Dr. James Baumgartner: Autologous Cord Blood Stem Cell Applications for Pediatric Stroke and Acquired Hearing Loss

Share the Science

Watch the recorded webinar to hear Dr. James Baumgartner, Surgical Director, Comprehensive Pediatric Epilepsy Center, Florida Hospital for Children, speak about using cord blood to treat acquired hearing loss and perinatal stroke in children.

 Webinar Summary

Perinatal stroke and acquired hearing loss are frequently occurring injuries in early life. Currently, there are no reparative treatment options available, and management focuses on augmenting the function of the injured cochlea and brain. Pre-clinical data suggest that progenitor cell infusions may allow for at least partial repair of these acquired central nervous system injuries. Human umbilical cord blood is an available stored progenitor cell population available for therapeutic use. In this webinar we will present preclinical data supporting the use of cord blood to treat acquired nervous system injury, and describe two ongoing clinical trials using autologous cord blood to treat acquired hearing loss and perinatal stroke in children.

You will learn:

  • The presentation and consequences of acquired hearing loss and perinatal stroke;
  • Current management strategies to treat acquired hearing loss and perinatal stroke;
  • Pre-clinical evidence for the use of cord blood to treat acquired hearing loss and perinatal stroke;
  • The current trial protocol to treat acquired hearing loss in children with autologous umbilical cord blood; and
  • The current trial protocol to treat perinatal stroke in children with autologous umbilical cord blood.

James Baumgartner, MD, discusses preclinical data supporting the use of cord blood to treat acquired nervous system injury, and describe two ongoing clinical trials using autologous cord blood to treat acquired hearing loss and perinatal stroke in children.

Speaker Bio

Dr. James Baumgartner is the Surgical Director of the Comprehensive Pediatric Epilepsy Center at the Florida Hospital for Children. His clinical focus is the surgical management of pharmaco-resistant epilepsy. As a board-certified pediatric neurosurgeon, he works in close collaboration with other members of our epilepsy team to treat children and adolescents, reducing the frequency and severity of seizures and in many cases, eliminating them entirely.

Dr. Baumgartner’s research concentrates on translational applications of autologous mesenchymal stem cell treatment of acquired nervous system injury. Before moving to Orlando, he participated in a pediatric trial using autologous bone marrow mononuclear fraction to treat severe traumatic brain injury within 48 hours of injury at the University of Texas-Houston Medical School. In Orlando, he has helped launch 4 trials using either human umbilical cord or bone marrow mononuclear fraction to treat acquired hearing loss and peri-natal stroke in infants and young children.

 

 

columbusMediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news and so much more. We look forward to having you on board for this exciting new series!